Raymond James & Associates Bridge Bio Pharma, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 13,004 shares of BBIO stock, worth $721,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,004

Previous 10,816 20.23%

Holding current value

$721,591

Previous $273,000 21.25%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$23.91 - $31.3 $52,315 - $68,484	2,188 Added 20.23%	13,004 $331,000
Q2 2024 Jul 19, 2024	BUY	$23.0 - $31.04 $45,977 - $62,048	1,999 Added 22.67%	10,816 $273,000
Q1 2024 Apr 22, 2024	SELL	$27.35 - $40.45 $7,001 - $10,355	-256 Reduced 2.82%	8,817 $272,000
Q4 2023 Jan 16, 2024	BUY	$24.02 - $43.89 $217,933 - $398,213	9,073 New	9,073 $366,000
Q2 2023 Jul 25, 2023	BUY	$13.29 - $18.01 $229,797 - $311,410	17,291 New	17,291 $297,000
Q4 2021 Feb 08, 2022	SELL	$11.38 - $53.41 $185,607 - $871,117	-16,310 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$46.87 - $64.24 $35,668 - $48,886	-761 Reduced 4.46%	16,310 $764,000
Q2 2021 Aug 11, 2021	SELL	$46.47 - $63.93 $882 - $1,214	-19 Reduced 0.11%	17,071 $1.04 Million
Q1 2021 May 14, 2021	SELL	$55.47 - $72.35 $35,500 - $46,304	-640 Reduced 3.61%	17,090 $1.05 Million
Q4 2020 Feb 12, 2021	BUY	$38.38 - $71.11 $680,477 - $1.26 Million	17,730 New	17,730 $1.26 Million

Others Institutions Holding BBIO

# of Institutions

409

Shares Held

187M

Call Options Held

11.3M

Put Options Held

2.2M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $8.23B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Bridge Bio Pharma, Inc. Transaction History